◆ 会议时间：2025年2月4-7日
◆ 会议地点：意大利 米兰
◆ 会议简介：
2025年第18届欧洲血友病及相关疾病协会(EAHAD)年会将于2025年2月4-7日在意大利米兰举行。大会组委会诚挚地邀请全球同事与朋友们参加这一传统的、十分独特的活动。EAHAD的目标是通过促进教育、支持研究和促进多学科方法来改善对遗传性或后天性出血性疾病患者的护理。一年一度的EAHAD大会是一个特别的机会，可以进一步增长我们的知识，更好地了解最新的科学进展，展示我们的最新发现，并积极与这一领域的医生、护士、物理治疗师和其他专家进行互动。上届会议总注册参会人数：3100名。
欧洲血友病和相关疾病协会（EAHAD）成立于2007年，是一个由致力于为患有血友病和其他出血性疾病的患者提供护理的医疗保健专业人士组成的多学科医学协会，成员包括血液学家、内科医生、儿科医生、护士、物理治疗师、实验室科学家和研究人员等。EAHAD的目标是为医学界相关人士和公众提供教育，宣促进科学研究，确保为患者提供最高质量的临床护理。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）
18th Annual Congress of The European Association for Haemophilia and Allied Disorders (EAHAD 2025)
Date: 4- 7 February 2024
Location: Milan, Italy
摘要征文投稿：
Abstract Submission Deadline: Wednesday, 23 October 2024
Notifications to submitters: early December 2024
Abstracts received after the deadline will not be accepted.
点此提交摘要>>>Submit Abstract>>>
EAHAD’s objectives are to foster scientific advancement in the field of inherited and acquired bleeding disorders in Europe, to encourage research and to provide a wide forum for discussion. Delegates who would like to present their work at the meeting, are invited to submit an abstract for consideration by the Scientific Committee.
Abstracts must describe original work, previously unpublished and not yet presented, at the time of the submission.
Scheduling abstract presentations is at the discretion of the Scientific Committee.
The abstracts will be peer-reviewed and those selected will be presented either as oral presentations or as posters.
For standardisation, the acceptable length of the abstract is of maximum 2500 characters. This includes the titles and non-visible characters, such as spaces and line breaks.
Abstract submitters will be asked their professional category during the submission process. Nurses, physiotherapists and psychosocial professionals will have the opportunity to display their posters during the Allied Health Professionals Day as well as during the Congress.
GENERAL GUIDELINES
Abstracts can only be submitted online via the abstract submission form.
Abstracts sent by post or email will not be accepted. No exceptions will be made.
- Abstracts can be saved in “Draft” status to be re-edited and modified until the submission deadline. Therefore, the submitter will be required to create a user account.
- Abstracts fulfilling all criteria can be saved in “Final submission” status. Only abstracts in “Final submission” status will be regarded as successfully submitted and considered for the Congress. The submitted / draft abstracts cannot be edited after the submission deadline.
- Abstracts are accepted on a wide range of topics in haemophilia and bleeding disorders. The submitter has to select the right topic for the abstract on the submission form. Available topics are:
- Haemophilia
- Haemophilia – Laboratory aspects, diagnostics
- Haemophilia – Preclinical
- Haemophilia – Clinical
- Von Willebrand Disease
- Von Willebrand Disease – Laboratory aspects, diagnostics
- Von Willebrand Disease – Preclinical
- Von Willebrand Disease – Clinical
- Other bleeding disorders
- Physiotherapy
- Nursing
- Psycho-social aspects
- The abstract should be structured into the following sections:
- A title which clearly indicates the nature of the investigation.
- Introduction should contain 1-2 sentences that clearly indicate the scientific question of the study and its clinical (or other) importance.
- Methods should contain sufficient information to be able to understand the experimental design, the analytical techniques and the statistics used in the study.
- Results should contain objective data to answer the scientific question(s).
- Discussions / Conclusions should provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralisation.
- No tables or figures are allowed in the abstract.
- Conflict of interest: It is the intent of EAHAD 2025 to provide high-quality sessions focused on educational content that is free from commercial influence or bias. Thus, the submitting author of an abstract is requested to declare any potential conflicts of interest for all authors during abstract submission.
- AI assistance: Authors must disclose in the “Methods” section of their abstract whether Artificial Intelligence (AI) – assisted technologies (such as Large Language Models [LLMs], chatbots etc.) – were used in the production of the submitted abstract and the reason they were used for (writing assistance, data collection and analysis, etc.). Chatbots (such as ChatGPT) should not be listed as authors.
- Abbreviations should be indicated in parentheses following their first mention in the text. Trade names cannot be mentioned in the title. However, trade names in brackets will be accepted in the body of the text.
- The submission of an abstract constitutes a formal commitment by the submitting (presenting) author to present the abstract (if accepted) in the session and the time assigned by the Programme Committee. Registration fees will not be waived.
- The presenting author of the abstract must be registered at the conference within 14 days of confirmation of abstract acceptance (the author will benefit from the early bird registration fee).
- Please ensure your abstract does not contain spelling, grammar, or scientific mistakes, as it will be reproduced exactly as submitted. Linguistic accuracy is your responsibility. No proofreading will be done. No changes can be made to the abstract after the submission deadline.
- Only original abstracts will be accepted and considered for the review.
Dear colleagues and friends,
On behalf of the EAHAD 2025 Organising Committee, it is my honour and pleasure to invite you to the 18th annual EAHAD Congress, taking place in Milan from 4 to 7 February 2025.
The mission of EAHAD is to promote education, support research, and improve clinical care and the lives of patients with inherited or acquired bleeding disorders. Our congress aims to be the quintessence of everything our association stands for.
This year’s scientific programme has been carefully designed to broaden the community’s understanding and spark discussions on the latest advancements in areas such as novel treatments, gene therapy, von Willebrand disease, implementation of AI in healthcare, management of elderly people with haemophilia and much more.
Internationally recognised speakers will share their insights and expertise, while our delegates will be able to present their research, exchange ideas, and network with fellow colleagues.
Within the vibrant metropolis of Milan, lies our home for EAHAD 2025, the MICO Congress Centre. A true testament to architectural ingenuity and innovation, the venue is located in the City Life area, which was designed in collaboration with the Iraqi-British architect and artist, Zaha Hadid.
Milan itself is a treasure-trove of elegance, style, history, culture, and gastronomy. From iconic landmarks such as the Duomo di Milano to the picturesque streets of Brera, every corner exudes charm and allure.
It is a truly special place and we hope to give you an equally special experience with our 18th annual congress.
Welcome to Milan. Welcome to EAHAD 2025.
Flora Peyvandi
EAHAD 2025 Congress President
◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。
|
